Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to development and licensing of ravidasvir (formerly PPI-668). Presidio’s current focus is on developing therapies for hepatitis C virus (HCV) infection. With a compound targeting the NS5A protein of HCV, Presidio is well positioned to compete in the HCV therapy market (see Programs & Pipeline for more details). Presidio’s goal is to advance its small-molecule, antiviral drug which is potent, offers pan-genotypic antiviral activity, offers convenient once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance.
Contact Us
Presidio Pharmaceuticals 